The effects of ICRF-154 in combination with other anticancer agents in vitro View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1992-08

AUTHORS

Y Kano, T Narita, K Suzuki, M Akutsu, K Suda, S Sakamoto, Y Miura

ABSTRACT

We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other), and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin, doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-11, cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for ICRF-154 in combination with cisplatin and methotrexate. The other drugs showed additive effects with ICRF-154. These results indicate that the combined effects of ICRF-154 with other agents vary, depending on the cell line. Against lymphoid malignancies, ICRF-154 would be advantageous when administered simultaneously with many anticancer agents. Of such agents, amsacrine, bleomycin, doxorubicin, and etoposide are the most suitable, while methotrexate is least suitable for such combined treatment. More... »

PAGES

281-286

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1992.257

DOI

http://dx.doi.org/10.1038/bjc.1992.257

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021497993

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1503899


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Burkitt Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Division", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Screening Assays, Antitumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia-Lymphoma, Adult T-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Razoxane", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Tochigi Cancer Center, Japan", 
          "id": "http://www.grid.ac/institutes/grid.420115.3", 
          "name": [
            "Division of Medical Oncology, Tochigi Cancer Center, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kano", 
        "givenName": "Y", 
        "id": "sg:person.0603027536.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603027536.70"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Narita", 
        "givenName": "T", 
        "type": "Person"
      }, 
      {
        "familyName": "Suzuki", 
        "givenName": "K", 
        "id": "sg:person.01202676124.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202676124.34"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Akutsu", 
        "givenName": "M", 
        "id": "sg:person.0717702563.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717702563.69"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Suda", 
        "givenName": "K", 
        "id": "sg:person.01331653227.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331653227.59"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Sakamoto", 
        "givenName": "S", 
        "id": "sg:person.014120017222.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014120017222.34"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Miura", 
        "givenName": "Y", 
        "id": "sg:person.01301423302.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301423302.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00685528", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077725830", 
          "https://doi.org/10.1007/bf00685528"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/226524a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014891537", 
          "https://doi.org/10.1038/226524a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02897198", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032684078", 
          "https://doi.org/10.1007/bf02897198"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/222384a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049481269", 
          "https://doi.org/10.1038/222384a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02899044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050764909", 
          "https://doi.org/10.1007/bf02899044"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1992-08", 
    "datePublishedReg": "1992-08-01", 
    "description": "We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other), and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin, doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-11, cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for ICRF-154 in combination with cisplatin and methotrexate. The other drugs showed additive effects with ICRF-154. These results indicate that the combined effects of ICRF-154 with other agents vary, depending on the cell line. Against lymphoid malignancies, ICRF-154 would be advantageous when administered simultaneously with many anticancer agents. Of such agents, amsacrine, bleomycin, doxorubicin, and etoposide are the most suitable, while methotrexate is least suitable for such combined treatment.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1992.257", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "66"
      }
    ], 
    "keywords": [
      "supra-additive effect", 
      "ICRF-154", 
      "protective effect", 
      "leukemia cell lines", 
      "cell lines", 
      "anticancer agents", 
      "lymphoblastic leukemia cell line", 
      "such combined treatment", 
      "additive effect", 
      "cell growth inhibition", 
      "erythroleukaemia cell line", 
      "cytosine arabinoside", 
      "CPT-11", 
      "drug combinations", 
      "lymphoid malignancies", 
      "human leukemia cell lines", 
      "ID50 level", 
      "isobologram method", 
      "Combined treatment", 
      "mitomycin C", 
      "methotrexate", 
      "MOLT-3", 
      "MTT assay", 
      "drugs", 
      "such agents", 
      "growth inhibition", 
      "bleomycin", 
      "etoposide", 
      "cisplatin", 
      "amsacrine", 
      "doxorubicin", 
      "agents", 
      "malignancy", 
      "vincristine", 
      "arabinoside", 
      "effect", 
      "treatment", 
      "inhibition", 
      "days", 
      "combination", 
      "assays", 
      "cells", 
      "lines", 
      "levels", 
      "presence", 
      "HSB", 
      "results", 
      "method"
    ], 
    "name": "The effects of ICRF-154 in combination with other anticancer agents in vitro", 
    "pagination": "281-286", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021497993"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1992.257"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1503899"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1992.257", 
      "https://app.dimensions.ai/details/publication/pub.1021497993"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_222.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1992.257"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.257'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.257'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.257'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.257'


 

This table displays all metadata directly associated to this object as RDF triples.

204 TRIPLES      21 PREDICATES      89 URIs      76 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1992.257 schema:about N0364f286a82a415db6a6d04d929e0da6
2 N12d75bf7de8243ed88fcf99eefd82b9b
3 N5a22e8b5f5884d1b892423da77ae889e
4 N673155b96717456f981ee7172682b23e
5 N688901903f0c4e699ba3302cd5d2b171
6 N7271012692b4499cb78c8444ee8946d0
7 N9a1e01dc5eef49bdb37f5f5a97188c0c
8 Nacf78aed1cd34ba6938ff352d9a779a4
9 Nb9628094ae3f4e2d82fb60f4216797a7
10 Nebe6038a36f746008715e58a6279cd8c
11 anzsrc-for:11
12 anzsrc-for:1115
13 schema:author N460943a0a2064a5cb73b586ad694e864
14 schema:citation sg:pub.10.1007/bf00685528
15 sg:pub.10.1007/bf02897198
16 sg:pub.10.1007/bf02899044
17 sg:pub.10.1038/222384a0
18 sg:pub.10.1038/226524a0
19 schema:datePublished 1992-08
20 schema:datePublishedReg 1992-08-01
21 schema:description We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other), and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin, doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-11, cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for ICRF-154 in combination with cisplatin and methotrexate. The other drugs showed additive effects with ICRF-154. These results indicate that the combined effects of ICRF-154 with other agents vary, depending on the cell line. Against lymphoid malignancies, ICRF-154 would be advantageous when administered simultaneously with many anticancer agents. Of such agents, amsacrine, bleomycin, doxorubicin, and etoposide are the most suitable, while methotrexate is least suitable for such combined treatment.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf Nd0f57101e9cd4432b9abd0e5657c68ae
25 Nfe0988b1e39d416f96470c67ddd19344
26 sg:journal.1017082
27 schema:keywords CPT-11
28 Combined treatment
29 HSB
30 ICRF-154
31 ID50 level
32 MOLT-3
33 MTT assay
34 additive effect
35 agents
36 amsacrine
37 anticancer agents
38 arabinoside
39 assays
40 bleomycin
41 cell growth inhibition
42 cell lines
43 cells
44 cisplatin
45 combination
46 cytosine arabinoside
47 days
48 doxorubicin
49 drug combinations
50 drugs
51 effect
52 erythroleukaemia cell line
53 etoposide
54 growth inhibition
55 human leukemia cell lines
56 inhibition
57 isobologram method
58 leukemia cell lines
59 levels
60 lines
61 lymphoblastic leukemia cell line
62 lymphoid malignancies
63 malignancy
64 method
65 methotrexate
66 mitomycin C
67 presence
68 protective effect
69 results
70 such agents
71 such combined treatment
72 supra-additive effect
73 treatment
74 vincristine
75 schema:name The effects of ICRF-154 in combination with other anticancer agents in vitro
76 schema:pagination 281-286
77 schema:productId N2373f54247e24cfab0a63d431ca578cb
78 N33c64b0a598e45dbb8f996bc35d641cc
79 Nf3190468e4ed4fafb9992b8f22dee2a3
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021497993
81 https://doi.org/10.1038/bjc.1992.257
82 schema:sdDatePublished 2022-09-02T15:47
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher Nac8994fb4cc147deae34f2507915750f
85 schema:url https://doi.org/10.1038/bjc.1992.257
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N0364f286a82a415db6a6d04d929e0da6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Razoxane
91 rdf:type schema:DefinedTerm
92 N04c0c0313b2741ae9d19c035f4de2dfa rdf:first sg:person.01331653227.59
93 rdf:rest N30203096ad7b4b91b4659d94de534dbc
94 N0ad78e84921b4eee933b80b1f6e9ead4 rdf:first sg:person.0717702563.69
95 rdf:rest N04c0c0313b2741ae9d19c035f4de2dfa
96 N12d75bf7de8243ed88fcf99eefd82b9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Cell Line
98 rdf:type schema:DefinedTerm
99 N1a6f85fca3934886bdb3547362582060 rdf:first sg:person.01301423302.39
100 rdf:rest rdf:nil
101 N2373f54247e24cfab0a63d431ca578cb schema:name pubmed_id
102 schema:value 1503899
103 rdf:type schema:PropertyValue
104 N2a619b1d04574cf8a53d23989b3f1bac rdf:first sg:person.01202676124.34
105 rdf:rest N0ad78e84921b4eee933b80b1f6e9ead4
106 N30203096ad7b4b91b4659d94de534dbc rdf:first sg:person.014120017222.34
107 rdf:rest N1a6f85fca3934886bdb3547362582060
108 N33c64b0a598e45dbb8f996bc35d641cc schema:name doi
109 schema:value 10.1038/bjc.1992.257
110 rdf:type schema:PropertyValue
111 N460943a0a2064a5cb73b586ad694e864 rdf:first sg:person.0603027536.70
112 rdf:rest Nf5aa2237eec44784a70d72a7966c22ba
113 N4c55698107434da3a367e4d588e71cb0 schema:familyName Narita
114 schema:givenName T
115 rdf:type schema:Person
116 N5a22e8b5f5884d1b892423da77ae889e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Drug Interactions
118 rdf:type schema:DefinedTerm
119 N673155b96717456f981ee7172682b23e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Drug Screening Assays, Antitumor
121 rdf:type schema:DefinedTerm
122 N688901903f0c4e699ba3302cd5d2b171 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Leukemia-Lymphoma, Adult T-Cell
124 rdf:type schema:DefinedTerm
125 N7271012692b4499cb78c8444ee8946d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Cell Division
127 rdf:type schema:DefinedTerm
128 N9a1e01dc5eef49bdb37f5f5a97188c0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Burkitt Lymphoma
130 rdf:type schema:DefinedTerm
131 Nac8994fb4cc147deae34f2507915750f schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 Nacf78aed1cd34ba6938ff352d9a779a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Humans
135 rdf:type schema:DefinedTerm
136 Nb9628094ae3f4e2d82fb60f4216797a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Dose-Response Relationship, Drug
138 rdf:type schema:DefinedTerm
139 Nd0f57101e9cd4432b9abd0e5657c68ae schema:issueNumber 2
140 rdf:type schema:PublicationIssue
141 Nebe6038a36f746008715e58a6279cd8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Antineoplastic Agents
143 rdf:type schema:DefinedTerm
144 Nf3190468e4ed4fafb9992b8f22dee2a3 schema:name dimensions_id
145 schema:value pub.1021497993
146 rdf:type schema:PropertyValue
147 Nf5aa2237eec44784a70d72a7966c22ba rdf:first N4c55698107434da3a367e4d588e71cb0
148 rdf:rest N2a619b1d04574cf8a53d23989b3f1bac
149 Nfe0988b1e39d416f96470c67ddd19344 schema:volumeNumber 66
150 rdf:type schema:PublicationVolume
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
155 schema:name Pharmacology and Pharmaceutical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1017082 schema:issn 0007-0920
158 1532-1827
159 schema:name British Journal of Cancer
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.01202676124.34 schema:familyName Suzuki
163 schema:givenName K
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202676124.34
165 rdf:type schema:Person
166 sg:person.01301423302.39 schema:familyName Miura
167 schema:givenName Y
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301423302.39
169 rdf:type schema:Person
170 sg:person.01331653227.59 schema:familyName Suda
171 schema:givenName K
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331653227.59
173 rdf:type schema:Person
174 sg:person.014120017222.34 schema:familyName Sakamoto
175 schema:givenName S
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014120017222.34
177 rdf:type schema:Person
178 sg:person.0603027536.70 schema:affiliation grid-institutes:grid.420115.3
179 schema:familyName Kano
180 schema:givenName Y
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603027536.70
182 rdf:type schema:Person
183 sg:person.0717702563.69 schema:familyName Akutsu
184 schema:givenName M
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717702563.69
186 rdf:type schema:Person
187 sg:pub.10.1007/bf00685528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077725830
188 https://doi.org/10.1007/bf00685528
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/bf02897198 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032684078
191 https://doi.org/10.1007/bf02897198
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/bf02899044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050764909
194 https://doi.org/10.1007/bf02899044
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/222384a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049481269
197 https://doi.org/10.1038/222384a0
198 rdf:type schema:CreativeWork
199 sg:pub.10.1038/226524a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014891537
200 https://doi.org/10.1038/226524a0
201 rdf:type schema:CreativeWork
202 grid-institutes:grid.420115.3 schema:alternateName Division of Medical Oncology, Tochigi Cancer Center, Japan
203 schema:name Division of Medical Oncology, Tochigi Cancer Center, Japan
204 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...